Insight journal – Dealtalk

Life Science Intelligence for Deal Makers
Dealtalk brings to you breaking news and the latest rumours of potential deals in the life science industry. Find out first who is partnering with who and the potential deal sizes.

Recent Dealtalk Insights

Inflammatory research shaped by personalised therapies

April 13, 2010 : big pharma, licensing, partnering

Rigel Pharma’s influence of shaping the future of inflammatory therapy has been highlighted again with the announcement that it has signed a $1.25 billion licensing agreement with Astra Zeneca for fostamatinib disodium. more »

Merial joins Intervet/Schering-Plough joint venture

April 9, 2010 : big pharma, joint venture, Merck, Sanofi

A new global player in the animal health sector has been created as a result of Sanofi-Aventis exercising its option from a deal announced back in September 2009. more »

Kinase targeted therapeutics are key to successful immuno-inflammatory treatments

April 9, 2010 : big pharma, GlaxoSmithKline, partnering, Pfizer

GSK continues to develop its drug discovery pipeline of products with the announcement it has formed an early stage agreement with Cellzome for its Episphere technology to develop and treat immuno-inflammatory disease. more »

Best partnering practices – just common sense, part 3

March 25, 2010 : best practice

We have been designing and organising specialised international partnering conferences since 1987 and in these 23 years I have seen several thousand partnering profiles, i.e. the composition with which conference registrants try to attract the interest of other registrants. more »

Novartis continues building option deal portfolio with Transgene’s TG4010

March 20, 2010 : big pharma, Novartis, option, partnering

Novartis has agreed an exclusive option for Transgene’s targeted immunotherapy product TG4010, in return for a non-refundable fee of $10 million. more »

Small molecule strategies continue to produce new COPD therapy targets

March 16, 2010 : big pharma, Merck, Nycomed, partnering, Roche

The development of small molecule therapies continues at pace with news that Roche is the latest company to license the Galapagos discovery platform to develop new treatments for COPD. more »

Cordis reaches coronary stent settlement with Boston Scientific

March 2, 2010 : settlement

The settlement between Cordis and Boston Scientific announced in February 2010 is the second agreement between the companies following a long running dispute. The litigation started several years ago as a result of disputed patents in the field of stents. more »

Best partnering practices – just common sense, part 2

February 16, 2010 : best practice

Part 1 of this article described how attendees of a partnering conference react if they receive an appointment request which is not justified by their own partnering interest profile and how they measure up the requesting delegate. more »

Cephalon acquires Mepha in deal valued at $615.4 million

February 10, 2010 : big pharma, Cephalon, M&A

Cephalon has once again demonstrated tremendous business acumen and expanded its range of pharmaceutical products and services within the developed and emerging markets with the acquisition of Mepha for $615.4 million. more »

Drug repurposing and repatenting

February 9, 2010 : Actavis, best practice, big pharma, Celgene, Eisai, Merck

Better scientific understanding of drug interactions with enzymes at the molecular level has allowed some old, ‘failed’ molecules to be used for novel purposes. more »

« Page 1 ... 83, 84, 85, 86, 87, 88, »

Recent company insights

Blog in Blog: There are no posts that match the selection criteria. View more company insights

Recent therapy insights

Blog in Blog: There are no posts that match the selection criteria. View more therapy insights

Recent technology insights

Blog in Blog: There are no posts that match the selection criteria. View more technology insights

Print Friendly, PDF & Email